The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 1.91 decrease increase over the last five trading days and traded at 3,306.41 points. The Index is up 19.25 percent year-to-date.
Last week the Investing News Network reported on a new Senate bill that seeks to add a more robust checkup system for medical devices connected to networks, which can be targeted by cyberattacks. INN also reported on the 64 drugs excluded from the latest  National Preferred Formulary (NPF) list. In the resolution to one of the most controversial cases from the pharmaceutical industry, “pharma bro” Martin Shkreli was found guilty of 3 out of five charges in front of a New York jury. “He is now almost certain to go to prison. Shkreli faces as long as 20 years behind bars, although he’s likely to serve much less,” as reported by Bloomberg.

• Cogentix Medical (NASDAQ:CGNT)
• Molecular Templates (NASDAQ:MTEM)
• Celldex Therapeutics (NASDAQ:CLDX)
• Cerus (NASDAQ:CERS)
• Kura Oncology (NASDAQ:KURA)

Cogentix Medical

Cogentix is an international endoscopy product manufacturer and supplier. Last week the company released their financial report for the second quarter of 2017, in it they revealed an 11 percent increase in the revenue produced from their urology products to $12.3 million.
“This growth was driven by impressive results from our PrimeSight product line, which grew 48% in the quarter, as our physician customers continue to embrace the always ready, always sterile value proposition PrimeSight offers,” president and CEO Darin Hammers said.
Cogentix Medical gained 17.07 percent last week and closed the week at $2.40 per share.

Molecular Templates

Molecular Templates is a biologic therapy company working on the development of the engineered toxin body technology. Last week the company announced it completed its merger with Threshold Pharmaceuticals (NASDAQ:THLD). Molecular Templates also reported a new collaboration agreement to develop novel oncology therapies with Takeda Pharmaceutical (TSE:4502).
Molecular Templates gained 16.51 percent last week and closed the week at $6.28 per share.

Celldex Therapeutics

Celldex is developing antibodies, antibody-drug conjugates and other protein-based therapeutics for the immune system set to inhibit tumors. Last week the company announced it will release their financial results for the second quarter of the year on August 8. Speculation alone seems to have propelled the company’s stock.
Celldex Therapeutics gained 9.57 percent last week and closed the week at $2.52 per share.

Cerus

Cerus is focused on the blood transfusion safety field. Their INTERCEPT Blood System reduces the risks in transfusion-transmitted infections. Last week the company reported its second quarter financials for the year, in which Cerus remarked its recently expanded agreement with the French National blood service based on INTERCEPT.
Cerus gained 9.51 percent last week and closed the week at $2.48 per share.

Kura Oncology

Kura is a clinical-stage biopharmaceutical company working on cancer treatments. Last week the company announced it was set to report its financial report for the second quarter of 2017 on August 7.
Kura Oncology gained 8.95 percent last week and closed the week at $10.35 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

** This article is updated each week. Please scroll to the top for the most recent information**

5 Top NASDAQ Biotech Stocks: Cytrx Leads the Week

July 30
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 1.02 decrease increase over the last five trading days and traded at 3,367.08 points. The Index is up 21.37 percent year-to-date.
Last week the GOP health care bill went to the Senate for debate but was halted by 3 Republican senators including John McCain, who was recently diagnosed with brain cancer. The path looks murky for a bill that has been campaigned against by patient and insurers groups alike. The Investing News Network (INN) reported on the result of AstraZeneca’S (NYSE:AZN) immunotherapy candidate failure and which company’s tech is next on the I/O space who can actually get a positive review and lead the pack.

• Cytrx (NASDAQ:CYTR)
• Novan (NASDAQ:NOVN)
• iRadimed (NASDAQ:IRMD)
• Compugen (NASDAQ:CGEN)
• Neptune (NASDAQ:NEPT)

Cytrx

Cytrx is a clinical stage biopharmaceutical company working on new cancer therapies. Last week the company announced a licensing partnership with NantCell for the exclusive rights to develop and commercialize aldoxorubicin for all indications.
Cytrx gained 37.17 percent last week and closed the week at $0.82 per share.

Novan

This late-stage pharmaceutical company has a focus on dermatology with five product candidates in several phases of development. Last week the company revealed on August 2, it will host a call with investors to provide an update on their recent progress. However, there haven’t been any other news to cause the stock increase.
Novan gained 31.11 percent last week and closed the week at $5.31 per share.

iRadimed

iRadimed is a medical device company overseeing production of MRI products and infusion therapy. Last week the company released their financial report for the second quarter of 2017, in it iRadimed reported $5.5 million in revenue for the quarter. The company recently re applied for a 510(k) with the FDA for a patient monitor.
iRadimed gained 17.37 percent last week and closed the week at $9.80 per share.

Cogentix Medical

Cogentix is an international endoscopy product manufacturer and supplier. Last week the company announced it acquired the privately held Genesis Medical, which is expected to produce revenue of over $2 million in 2018.
Cogentix Medical gained 12.02 percent last week and closed the week at $2.05 per share.

Neptune

Neptune offers a variety of health products including krill oil. Last week the company received a notification from the NASDAQ about it’s delisting due to accounting 30 days with its stock valued under the minimum $! Requirement. There was no real indication as to the stock activity.
Neptune gained 8.21 percent last week and closed the week at $0.87 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.